

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 14, 2006

Signature: 
(Lynn L. Janis)

Docket No.: 28646/42100
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:
Hans J. Strauss et al.

Application No.: 10/581,773

Filed: June 6, 2006

Art Unit: Not Yet Assigned

For: THERAPEUTICALLY USEFUL
MOLECULES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. §1.97(b)(3)). Applicants submit herewith copies of non-patent literature in accordance with 37 C.F.R. §1.98(a)(2).

In accordance with 37 C.F.R. §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to

Application No.: 10/581,773

Docket No.: 28646/42100

be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm except for the Issue Fee) to our Deposit Account No. 13-2855, under Order No. 28646/42100. A copy of this paper is enclosed.

Dated: November 14, 2006

Respectfully submitted,

By 
Lynn L. Janulis

Registration No.: 53,066
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicants



Approved for use through 03/31/2007. OMB 0551-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449(PTO)				Complete if Known	
				Application Number	10/581,773
				Filing Date	June 6, 2006
				First Named Inventor	Hans J. Strauss
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	28646/42100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	WO 00/26249	05-11-2000	Imperial College Innovations Ltd. et al.	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C1	BELLANTUNO et al., "Two Distinct HLA-A0201-Presented Epitopes of the Wilms Tumor Antigen 1 Can Function as Targets for Leukemia-Reactive CTL," <i>Blood</i> 100:3835-3837 (2002).			
	C2	BOULTER et al., "Stable, Soluble T-Cell Receptor Molecules for Crystallization and Therapeutics," <i>Protein Eng.</i> 16:707-711 (2003).			
	C3	CHUNG et al., "Functional Three-Domain Single-Chain T-Cell Receptors," <i>Proc. Natl. Acad. Sci. USA</i> 91:12654-12658 (1994).			
	C4	DUDLEY et al., "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes," <i>Science</i> 298:850-854 (2002).			
	C5	ENGELS et al., "Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes," <i>Human Gene Ther.</i> 14:1155-1168 (2003).			
	C6	ESHMAR et al., "Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-Binding Domains and the γ or ζ Subunits of the Immunoglobulin and T-Cell Receptors," <i>Proc. Natl. Acad. Sci. USA</i> 90:720-724 (1993).			
	C7	FINER et al., "Kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," <i>Blood</i> 83:43-50 (1994).			
	C8	GAO et al., "Selective Elimination of Leukemic CD34+ Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1," <i>Blood</i> 95:2198-2203 (2000).			
	C9	GAO et al., "Human Cytotoxic T Lymphocytes Specific for Wilms' Tumor Antigen-1 Inhibit Engraftment of Leukemia-Initiating Stem Cells in Non-Obese Diabetic-Severe Combined Immunodeficient Recipients," <i>Transplantation</i> 75:1429-1436 (2003).			
	C10	GARCIA et al., "Structural Basis of T Cell Recognition," <i>Ann. Rev. Immunol.</i> 17:369-397 (1999).			
	C11	HWU et al., "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed by an Antibody Variable Region and the Fc Receptor γ Chain," <i>J. Exp. Med.</i> 178:361-366 (1993).			

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/581,773
				Filing Date	June 6, 2006
				First Named Inventor	Hans J. Stauss
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	28646/42100

	C12	INOUE et al., "Long-Term Follow-Up of Minimal Residual Disease in Leukemia Patients by Monitoring WT1 (Wilms Tumor Gene) Expression Levels," <i>Blood</i> 88:2267-2278 (1996).	
	C13	INOUE et al., "Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia," <i>Blood</i> 89:1405-1412 (1997).	
	C14	INOUE et al., "Wilms' Tumor Gene (WT1) Competes with Differentiation-Inducing Signal in Hematopoietic Progenitor Cells," <i>Blood</i> 91:2969-2976 (1998).	
	C15	KAST et al., "Eradication of Adenovirus E1-Induced Tumors by E1A-Specific Cytotoxic T Lymphocytes," <i>Cell</i> 59:603-614 (1989).	
	C16	KAWAKAMI et al., "Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection," <i>Proc. Natl. Acad. Sci. USA</i> 91:6458-6462 (1994).	
	C17	KESSELIS et al., "Changing T Cell Specifically by Retroviral T Cell Receptor Display," <i>Proc. Natl. Acad. Sci. USA</i> 97:14578-14583 (2000).	
	C18	LEFRANC et al., "IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains and Ig Superfamily V-Like Domains," <i>Dev. Comp. Immunol.</i> 27:55-77 (2003).	
	C19	MENSSEN et al., "Wilms' Tumor Gene (WT1) Expression in Lung Cancer, Colon Cancer and Glioblastoma Cell Lines Compared to Freshly Isolated Tumor Specimens," <i>J. Cancer Res. Clin. Oncol.</i> 126:226-232 (2000).	
	C20	MENSSEN et al., "Presence of Wilms' Tumor Gene (WT1) Transcripts and the WT1 nuclear Protein in the Majority of Human Acute Leukemias," <i>Leukemia</i> 9:1060-1067 (1995).	
	C21	MENSSEN et al., "Detection by Monoclonal Antibodies of the Wilms' Tumor (WT1) Nuclear Protein in Patients with Acute Leukemia," <i>Int. J. Cancer</i> 70:518-523 (1997).	
	C22	MIYOSHI, "High Expression of Wilms' Tumor Suppressor Gene Predicts Poor Prognosis in Breast Cancer Patients," <i>Clin. Cancer Res.</i> 8:1167-1171 (2002).	
	C23	MORITZ et al., "Cytotoxic T Lymphocytes with a Grafted Recognition Specifically for ERBB2-Expressing Tumor Cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:4318-4322 (1994).	
	C24	OGAWA et al., "Successful Donor Leukocyte Transfusion at Molecular Relapse for a Patient with Acute Myeloid Leukemia Who Was Treated with Allogeneic Bone Marrow Transplantation: Importance of the Monitoring of Minimal Residual Disease by WT1 Assay," <i>Bone Marrow Transplantation</i> 21:525-527 (1998).	
	C25	OJI et al., "Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth," <i>Jpn J. Cancer Res.</i> 90:194-204 (1999).	
	C26	OJI et al., "Overexpression of the Wilms' Tumor Gene WT1 in Head and Neck Squamous Cell Carcinoma," <i>Cancer Sci.</i> 94:523-529 (2003).	
	C27	OJI et al., "Overexpression of the Wilms' Tumor Gene WT1 in Primary Thyroid Cancer," <i>Cancer Sci.</i> 94:606-611 (2003).	
	C28	OJI et al., "Overexpression of the Wilms' Tumor Gene WT1 in Colorectal Adenocarcinoma," <i>Cancer Sci.</i> 94:712-717 (2003).	
	C29	ROBERTS et al., "Targeting of Human Immunodeficiency Virus-Infected Cells by CD8+ T Lymphocytes Armed with Universal T-Cell Receptors," <i>Blood</i> 84:2878-2889 (1994).	
	C30	RODECK et al., "Expression of the WT1 Wilms' Tumor Gene by Normal and Malignant Human Melanocytes," <i>Int. J. Cancer</i> 59:78-82 (1994).	
	C31	SILBERSTEIN et al., "Altered Expression of the WT1 Wilms Tumor Suppressor Gene in Human Breast Cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94:8132-8137 (1997).	
	C32	STANISLAWSKI et al., "Circumventing Tolerance to a Human MDM2-Derived Tumor Antigen by TCR Gene Transfer," <i>Nat. Immunol.</i> 2:962-970 (2001).	

Examiner Signature	Date Considered
--------------------	-----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/581,773
				Filing Date	June 6, 2006
				First Named Inventor	Hans J. Strauss
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	28646/42100

C33	TAMAKI et al., "Increased Expression of Wilms Tumor Gene (WT1) at Relapse in Acute Leukemia," <i>Blood</i> 88:4396-4398 (1996).	
C34	UEDA et al., "Overexpression of the Wilms' Tumor Gene WT1 in Human Bone and Soft-Tissue Sarcomas," <i>Cancer Sci.</i> 94:271-276 (2003).	
C35	VIEL et al., "Molecular Mechanisms Possibly Affecting WT1 Function in Human Ovarian Tumors," <i>Int. J. Cancer</i> 57:515-521 (1994).	
C36	XUE et al., "Elimination of Human Leukemia Cells in NOD/SCID Mice by WT1-TCR Gene-Transduced Human T Cells," <i>Blood</i> 106:3062-3067 (2005).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zachary Skelding/	Date Considered	12/30/2009
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./



PTO/ISB/92 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Small Business Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/581,773

Attorney Docket No.: 28646/42100

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 14, 2006
Date

A handwritten signature in black ink, appearing to read "Lynn L. Janulis".

Signature

Lynn L. Janulis

Typed or printed name of person signing Certificate

53,066
Registration Number, if applicable

(312) 474-6637
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (37 References) (3 pages)